Availability, Patient Preference, and Linvoseltamab: What Pharmacists Need to Know About the Evolving Bispecific Landscape

This episode, titled 'Availability, Patient Preference, and Linvoseltamab: What Pharmacists Need to Know About the Evolving Bispecific Landscape,' features oncology pharmacists discussing the following critical questions:

Off-the-shelf availability was one of the most consistently cited advantages of bispecific therapy across all three forum sites. In practice, how much does immediate availability actually change the clinical decision?

Let's talk about linvoseltamab specifically. Setting aside efficacy comparisons for a moment, what do pharmacists need to understand about how it differs operationally from other bispecifics they may already be using?

Led by the moderator, the panelists examined how the off-the-shelf availability of bispecific antibodies factors into clinical decision-making relative to CAR-T therapy, noting that while immediate availability is a meaningful advantage, the decision between the two modalities is ultimately patient-driven, with some patients preferring the time-limited, one-and-done appeal of CAR-T and others preferring the consistent, ongoing treatment cadence of a bispecific antibody that gradually spaces out from weekly to monthly dosing over time. The discussion also highlighted how patient preference, social support, geography, and provider scheduling realities all factor meaningfully into bispecific agent selection in practice, with no head-to-head trial data available to definitively favor one modality over the other, reinforcing that a transparent, patient-centered conversation presenting both options remains the most appropriate framework for shared decision-making. The panelists further outlined what pharmacists need to understand about linvoseltamab's distinct operational profile, emphasizing that its weekly step-up dosing schedule, compared to the multi-day inpatient observation requirements of other agents, represents a meaningful practical advantage for patients who travel long distances for treatment and for community practices where providers rotate across multiple locations on limited schedules, making linvoseltamab a particularly accessible and logistically streamlined option for appropriate late-line patients in community oncology settings.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

The next episode in this series, 'Sequencing in Focus: Pharmacists Reflect on the Impacts of MajesTEC-3 and MajesTEC-9 Data in Myeloma,' features the panelists advancing their conversation on multiple myeloma and focusing on how the MajesTEC-3 data for teclistamab plus daratumumab and the newly presented MajesTEC-9 data for teclistamab monotherapy are shaping sequencing decisions.